Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3-4
pubmed:dateCreated
2004-5-25
pubmed:abstractText
Fulminant hepatic failure (FHF) attributes to rising medical cost and accounts for many deaths each year in the United States. Currently, the only solution is organ transplantation. Due to increasing donor organ shortage, many in need of transplantation continue to remain on the waiting list. Liver Assist Devices (LADs) are being used to temporarily sustain liver function and bridge the period between FHF and transplantation. Hepatic Tissue Engineering is a step toward alleviating the need for donor organs; yet many challenges must be overcome including scaffold choice, cell source and immunological barriers. Bioreactors have aided in hepatocyte survival and have proven to sustain viable cells for several weeks. Achieving the necessary functions required for hepatic replacement is aided by the incorporation of growth factors and mitogens many that now can be bound to the polymer scaffold and released in a timely manner. Utilizing concepts such as MicroElectroMechanical systems (MEMs) technology, our laboratory is able to mimic the natural vasculature of the liver and sustain functional and viable hepatocytes. Expanding and improving upon this platform technology, advancements made will continue toward the development of a fully functioning and implantable liver.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0966-3274
pubmed:author
pubmed:copyrightInfo
Copyright 2004 Elsevier B.V.
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
303-10
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Hepatic tissue engineering.
pubmed:affiliation
Massachusetts General Hospital, Warren 11, 55 Fruit Street, Boston, MA 02114, USA.
pubmed:publicationType
Journal Article, Review